Next-generation treatments for Fragile X syndrome

November 29, 2012

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

Fragile X syndrome (FXS), the most common heritable form of autism and , is one of the most exciting areas in at the moment.

A decade ago, Dr. Mark Bear and his colleagues discovered that an animal model for FXS was associated with a distinctive alteration in , enhanced long-term depression, which was mediated by a specific mechanism, enhanced signaling via the metabotropic glutamate receptor 5 (mGluR5). Dr. Bear and his colleagues proceeded to show that blocking mGluR5 showed promise in animal models as the first treatment for FXS. A recent preliminary study of the drug fenobam, an mGluR5 blocker, provided hints of some beneficial effects in adults with FXS.

mGluR5 blockers are likely to be the first examples of several therapeutic mechanisms that will emerge in upcoming years. Now, Ciranna and colleagues have identified another potential therapeutic mechanism for FXS.

Using a mouse model of FXS, they demonstrate that blockade of the serotonin 7 (5-HT7) receptor, like mGluR5 blockade, reduces long-term depression mediated by mGlu receptors. In neuroscience, long-term depression is the term used to describe a reduction or decrease in the effectiveness of , meaning that the ability of to communicate is diminished.

The effect that they detected occurred in the hippocampus, one of the brain structures most crucially involved in .

"This result opens new perspectives in the therapy of Fragile X Syndrome, suggesting that selective agonists for 5-HT7 receptors might become useful pharmacological tools," said Ciranna.

This led them to study the effects of LP-211, a new compound with a high affinity and selectivity for 5-HT7 receptors. The data showed that LP-211 behaves as an agonist of 5-HT7 receptors and therefore, may be used as a potential treatment for , although much more work would be necessary before it could be tested in humans.

"This study illustrates a critical issue in the development of new treatments for psychiatric disorders. It is uncommon that all patients with a particular disorder will tolerate or respond to a single treatment. Thus, we need multiple approaches to treatment," commented Dr. John Krystal, Editor of . "Further, this study illustrates how a single insight into the biology of an illness, in this case enhanced mGluR5 signaling, yields multiple novel mechanisms that might be explored to develop novel treatments."

Explore further: Fragile X syndrome can be reversed in adult mouse brain

More information: The article is "Activation of 5-HT7 Serotonin Receptors Reverses Metabotropic Glutamate Receptor-Mediated Synaptic Plasticity in Wild-Type and Fmr1 Knockout Mice, a Model of Fragile X Syndrome" by Lara Costa, Michela Spatuzza, Simona D'Antoni, Carmela M. Bonaccorso, Chiara Trovato, Sebastiano A. Musumeci, Marcello Leopoldo, Enza Lacivita, Maria V. Catania, and Lucia Ciranna (doi: 10.1016/j.biopsych.2012.06.008). The article appears in Biological Psychiatry, Volume 72, Issue 11 (December 1, 2012).

Related Stories

Fragile X syndrome can be reversed in adult mouse brain

April 11, 2012
A recent study finds that a new compound reverses many of the major symptoms associated with Fragile X syndrome (FXS), the most common form of inherited intellectual disability and a leading cause of autism. The paper, published ...

Most common form of inherited intellectual disability may be treatable

May 17, 2011
Advancements over the last 10 years in understanding intellectual disability (ID, formerly mental retardation), have led to the once-unimaginable possibility that ID may be treatable, a review of more than 100 studies on ...

Neuroscientists find promise in addressing Fragile X afflictions

September 19, 2012
Neuroscientists at New York University have devised a method that has reduced several afflictions associated with Fragile X syndrome (FXS) in laboratory mice. Their findings, which are reported in the journal Neuron, offer ...

Recommended for you

Study examines effects of stopping psychiatric medication

July 20, 2017
Despite numerous obstacles and severe withdrawal effects, long-term users of psychiatric drugs can stop taking them if they choose, and mental health care professionals could be more helpful to such individuals, according ...

Study finds gene variant increases risk for depression

July 20, 2017
A University of Central Florida study has found that a gene variant, thought to be carried by nearly 25 percent of the population, increases the odds of developing depression.

In making decisions, are you an ant or a grasshopper?

July 20, 2017
In one of Aesop's famous fables, we are introduced to the grasshopper and the ant, whose decisions about how to spend their time affect their lives and future. The jovial grasshopper has a blast all summer singing and playing, ...

Perceiving oneself as less physically active than peers is linked to a shorter lifespan

July 20, 2017
Would you say that you are physically more active, less active, or about equally active as other people your age?

New study suggests that reduced insurance coverage for mental health treatment increases costs for the seriously ill

July 19, 2017
Higher out-of-pocket costs for mental health care could have the unintended consequence of increasing the use of acute and involuntary mental health care among those suffering from the most debilitating disorders, a Harvard ...

Old antibiotic could form new depression treatment

July 19, 2017
An antibiotic used mostly to treat acne has been found to improve the quality of life for people with major depression, in a world-first clinical trial conducted at Deakin University.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.